Welcome to our dedicated page for Masimo news (Ticker: MASI), a resource for investors and traders seeking the latest updates and insights on Masimo stock.
Masimo Corporation (MASI) delivers innovative noninvasive monitoring technologies and premium audio solutions across global markets. This news hub provides investors and industry professionals with timely updates directly from corporate communications and verified financial sources.
Access official press releases covering Masimo's healthcare innovations, including sensor technology advancements and hospital automation systems, alongside developments in its consumer audio division. Our repository tracks regulatory filings, partnership announcements, and clinical validation studies while maintaining strict editorial neutrality.
Key updates include quarterly earnings disclosures, product launch details across both business segments, and strategic corporate actions. Bookmark this page for streamlined monitoring of Masimo's operational milestones and market-moving events in the medical technology sector.
Masimo has received FDA clearance for its SedLine brain function monitoring technology for pediatric patients aged 1-17 in the United States. This advancement allows for enhanced monitoring of brain activity during anesthesia, with specialized sensors designed for smaller foreheads. The SedLine system utilizes advanced signal processing of EEG signals to provide detailed insights for clinicians, aiming to improve safety and efficacy during pediatric anesthesia.
Sound United, a leader in premium audio products, has agreed to be acquired by Masimo (NASDAQ: MASI), a global medical technology company. This strategic acquisition aims to combine Masimo's healthcare strengths with Sound United's consumer electronics expertise, enhancing product distribution and consumer experience. The partnership will utilize Sound United’s extensive brand portfolio and global reach to improve Masimo's consumer product offerings. The transaction is anticipated to close in mid-2022, pending regulatory approvals.
Masimo reported a 11.0% increase in product revenue for Q4 2021, totaling $327.6 million, and an 8.3% increase for the full year, reaching $1,239.2 million. GAAP net income for Q4 was $68.3 million or $1.18 per diluted share, while full-year GAAP net income stood at $229.6 million, $3.98 per share. 2022 guidance estimates product revenue at $1,350 million. Additionally, Masimo plans to acquire Sound United for approximately $1.025 billion, expected to bolster their consumer health technology strategy.
Masimo (NASDAQ: MASI) has expanded its Masimo SafetyNet platform to incorporate advanced telehealth capabilities, allowing for robust video-based virtual consultations alongside continuous remote monitoring. This update enhances patient care by enabling clinicians to perform multi-way virtual appointments through a single smartphone app, integrating vital sign monitoring and enhanced communication tools. The platform now supports a wider range of patients, including post-surgical and chronic condition cases, streamlining care from hospital to home.
Masimo (NASDAQ: MASI) and Temple University Hospital have expanded their partnership, integrating the Centroid™ patient monitoring system across 100 ICU beds. This advanced wireless technology supports clinicians by monitoring patient position, respiratory rates, and alerting for fall-like events. Centroid aims to reduce hospital-acquired pressure injuries (HAPIs), which affect nearly 5% of hospitalized patients in the U.S., resulting in significant treatment costs. The collaboration enhances patient safety and care efficiency, marking a step forward in Masimo's commitment to improving healthcare outcomes.
Masimo (NASDAQ: MASI) announced findings from a study presented at the Society for Technology in Anesthesia 2022 Annual Meeting. The research evaluated pulse oximetry data, concluding no significant bias based on ethnicity between black and white volunteers. The study, analyzing 7,183 paired samples, found a 0.15% difference in bias—0.20% for black subjects and 0.05% for white subjects—deemed clinically insignificant. These results challenge previous claims of racial bias in pulse oximetry, asserting Masimo's technology meets accuracy specifications.
Masimo (NASDAQ: MASI) reported findings from a study presented at the Society for Technology in Anesthesia 2022 Annual Meeting. The study analyzed pulse oximetry data and found no significant bias based on ethnicity among black and white subjects monitored with Masimo's SET® pulse oximetry technology. The analysis included 7,183 paired samples and revealed that the bias difference was 0.15%, which is not clinically significant. Masimo plans to conduct additional studies to further explore these findings.
Masimo Corporation (NASDAQ: MASI) has announced preliminary financial results for the full year 2021 and guidance for 2022. For 2021, product revenues are projected between $1,235 million and $1,240 million, representing an increase of approximately 8.0% to 8.4%. The company expects GAAP and non-GAAP earnings per diluted share to exceed earlier guidance of $3.88. Looking ahead, Masimo forecasts product revenue of approximately $1,350 million and GAAP earnings per diluted share of $4.27 for 2022. The fourth quarter results will be discussed on February 15, 2022.
Masimo (NASDAQ: MASI) revealed findings from a prospective study published in Anesthesia & Analgesia highlighting a correlation between EEG-based markers and postoperative delirium (POD) in older elective surgery patients. Out of 237 patients, 17% developed POD, with lower preoperative spectral edge frequency (SEF) and gamma-band power linked to increased risk. The study suggests EEG markers could assist in identifying at-risk patients, emphasizing the importance of brain function monitoring for improving outcomes in geriatric surgery.
Masimo (NASDAQ: MASI) announced the results of a study published in Clinical Medicine Insights: Pediatrics, showing the effectiveness of its Rad-G® Pulse Oximeter in detecting pneumonia in over 4,500 children under five in India. The study indicated that Rad-G helped achieve over 91% accurate case management of acute respiratory infections, reducing unnecessary antibiotic use. Researchers noted that Rad-G's usability and reliability make it suitable for low-resource settings, potentially transforming pneumonia diagnosis. The study highlights the critical need for improved pneumonia management tools in India, where pneumonia contributes to significant child mortality.
